ResMed Inc., a leader in the biotech sector, has been experiencing significant company events included in our report. Notably, multiple financial institutions like
UNIVEST FINANCIAL Corp,
BNP PARIBAS ASSET MANAGEMENT Holding S.A., and
Bessemer Group Inc, have done transactions related to ResMed's stock, either by selling or increasing its share. The company has also been a subject of varying investor sentiments, with
Robert W. Baird and
Mizuho adjusting price targets for the stock, while it has also made notable earnings reports, including that for Q1 FY2026, which reflected
EPS at $2.37 and
revenue hitting $1.3 billion. The National Pension Service and Wealth Alliance LLC are among institutions that have invested considerably in
$RMD. Meanwhile, CEO
Michael Farrell sold 8,011 shares. ResMed is showing strong growth potential, surpassing Q4 earnings and revenue estimates, with further launches in new mask platforms while investing in U.S. Operations further solidifies this sentiment.
Resmed RMD News Analytics from Wed, 23 Apr 2025 07:00:00 GMT to Sat, 15 Nov 2025 23:42:13 GMT -
Rating 9
- Innovation 7
- Information 6
- Rumor -2
